Clinical trial · no report yet · Phase 2
VICCURO21103
Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study
- NCT05361720 ↗
- Recruiting
- Vanderbilt-Ingram Cancer Center
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 18 | |
| YouTube | 8 | |
| Podcasts | 4 |
The trial
ClinicalTrials.gov- Official title
- Optimal Treatment by Invoking Biologic Clusters in Renal Cell Carcinoma (OPTIC RCC)
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma; Stage III Renal Cell Cancer AJCC v8; Stage IV Renal Cell Cancer AJCC v8
- Interventions
- Cabozantinib; Ipilimumab; Nivolumab
- Arms
- Arm I (ipilimumab, nivolumab) · Experimental
- Arm II (nivolumab, cabozantinib) · Experimental
- Enrollment
- 54 (estimated)
- Primary outcomes
- Overall response rate (ORR) (Arm 1)
- Overall response rate (Arm 2)
- Sponsor
- Vanderbilt-Ingram Cancer Center with National Cancer Institute (NCI), United States Department of Defense
- Start
- Dec 6, 2022
- Primary completion
- Oct 1, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05361720 · updated Aug 19, 2026